NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis $1.40 -0.02 (-1.41%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Traws Pharma Stock (NASDAQ:TRAW) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Traws Pharma alerts:Sign Up Key Stats Today's Range$1.35▼$1.4350-Day Range$1.33▼$1.6952-Week Range$0.97▼$19.44Volume33,884 shsAverage Volume511,269 shsMarket Capitalization$9.88 millionP/E Ratio0.02Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Read More Traws Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks36th Percentile Overall ScoreTRAW MarketRank™: Traws Pharma scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Traws Pharma. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Traws Pharma is 0.02, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.65.Price to Earnings Ratio vs. SectorThe P/E ratio of Traws Pharma is 0.02, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 31.45.Price to Book Value per Share RatioTraws Pharma has a P/B Ratio of 1.20. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Traws Pharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.10% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Traws Pharma has recently decreased by 36.45%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTraws Pharma does not currently pay a dividend.Dividend GrowthTraws Pharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.10% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Traws Pharma has recently decreased by 36.45%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News SentimentN/A News SentimentTraws Pharma has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Traws Pharma this week, compared to 2 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Traws Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders13.60% of the stock of Traws Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.95% of the stock of Traws Pharma is held by institutions.Read more about Traws Pharma's insider trading history. Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAW Stock News HeadlinesTraws Pharma, Inc.: Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | finanznachrichten.deTraws Pharma receives approval to proceed with Phase 2 COVID studiesAugust 18, 2025 | msn.comThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.August 29 at 2:00 AM | Paradigm Press (Ad)Traws Pharma Gains Approval for Phase 2 COVID-19 TrialsAugust 18, 2025 | msn.comTraws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025August 18, 2025 | globenewswire.comTraws Pharma Reports Q2 Results, Advances COVID-19 and Influenza Antiviral ProgramsAugust 16, 2025 | msn.comTraws Pharma Advances Antiviral Programs Amid Revenue GrowthAugust 16, 2025 | theglobeandmail.comTraws Pharma, Inc. (NASDAQ:TRAW) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | insidermonkey.comSee More Headlines TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed this year? Traws Pharma's stock was trading at $8.88 at the beginning of the year. Since then, TRAW stock has decreased by 84.2% and is now trading at $1.40. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) posted its earnings results on Thursday, August, 14th. The company reported ($0.11) EPS for the quarter, beating analysts' consensus estimates of ($8.75) by $8.64. The company had revenue of $2.73 million for the quarter, compared to the consensus estimate of $0.06 million. Traws Pharma had a net margin of 3,028.25% and a negative trailing twelve-month return on equity of 1,812.48%. Read the conference call transcript. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Traws Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Aptinyx (APTX). Company Calendar Last Earnings8/14/2025Today8/29/2025Next Earnings (Estimated)11/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRAW Previous SymbolNASDAQ:TRAW CIK1130598 Webwww.onconova.com Phone267-759-3680Fax267-759-3681Employees17Year FoundedN/AProfitability EPS (Trailing Twelve Months)$88.83 Trailing P/E Ratio0.02 Forward P/E RatioN/A P/E GrowthN/ANet Income-$166.52 million Net Margins3,028.25% Pretax Margin-613.92% Return on Equity-1,812.48% Return on Assets512.72% Debt Debt-to-Equity RatioN/A Current Ratio2.09 Quick Ratio2.09 Sales & Book Value Annual Sales$230 thousand Price / Sales43.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.17 per share Price / Book1.21Miscellaneous Outstanding Shares7,060,000Free Float6,103,000Market Cap$10.03 million OptionableOptionable Beta1.14 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:TRAW) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.